Leaflet LAGEVRIO 200mg hard capsules

Product code:
W530950089
Quantity:
40
Indicated for:
COVID-19
Route of administration:
oral
Substance:
molnupiravir (antiviral)
ATC
J05AB18 — Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Precautions:

Dose adjustment in renal impairment

Dose adjustment may be needed in kidney disease.

Major drug interactions

This medicine may have important interactions with other medicines.

Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning

Use during pregnancy only on medical advice.

Molnupiravir is an antiviral medication used for the treatment of COVID-19 in patients with mild to moderate disease who are at high risk of progressing to severe illness. It works by inhibiting the replication of the SARS-CoV-2 virus, thereby reducing viral load.

The medication is taken orally, usually twice daily for five days. It is effective in reducing the risk of hospitalization and death in high-risk patients.

Side effects may include nausea, diarrhea, dizziness, and headache. Currently, its use is limited to certain patient groups, and its long-term safety is still under investigation.

Consult your doctor to discuss whether Molnupiravir is suitable for you. It is important to follow the prescribed dosage and adhere to all medical recommendations.

Official documents

Added to database:
04/11/2011

General data about LAGEVRIO 200mg

Substance:
molnupiravir
Product code:
W530950089
Concentration:
200mg
Pharmaceutical form:
hard capsules
Quantity:
40
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
Merck Sharp & Dohme B.V. - OLANDA
Holder:
Merck Sharp & Dohme (UK) Limited - UK
Number:
PLGB 53095/0089